Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 12/20 | 1.00 |
| ▸ | DRD2 | P14416 | 3/20 | 0.61 |
| ▸ | DRD4 | P21917 | 2/20 | 0.61 |
| ▸ | DRD3 | P35462 | 2/20 | 0.61 |
| ▸ | HTR3A | P46098 | 2/20 | 0.60 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.60 |
| ▸ | HTR3B | O95264 | 1/20 | 0.60 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.60 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL726793 | 0.99 | HTR4 (0.98) | HTR4DRD2DRD4DRD3HTR3A | |
| Hydrochloric Acid SCHEMBL7035321 | 0.99 | HTR4 (0.98) | HTR4DRD2DRD4DRD3HTR3A | |
| Hydrochloric Acid SCHEMBL9021660 | 0.92 | HTR4 (0.86) | HTR4DRD2DRD4DRD3HTR3A | |
| SCHEMBL8274637 | 0.91 | HTR4 (0.83) | HTR4DRD2DRD4DRD3 | |
| SCHEMBL19397170 | 0.88 | HTR4 (0.79) | HTR4DRD2DRD4DRD3HTR3A | |
| Hydrochloric Acid SCHEMBL7388264 | 0.84 | HTR4 (0.73) | HTR4DRD2DRD4DRD3HTR3A | |
| SCHEMBL14827434 | 0.84 | HTR4 (0.72) | HTR4DRD2DRD4DRD3HTR3A | |
| SCHEMBL16403692 | 0.84 | HTR4 (0.72) | HTR4DRD2DRD4DRD3HTR3A | |
| SCHEMBL14827422 | 0.84 | HTR4 (0.75) | HTR4DRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL7388262 | 0.83 | HTR4 (0.71) | HTR4DRD2DRD4DRD3HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190092727-A1 | Piperidine Compounds, Pharmaceutical Composition Comprising The Same And Its Use | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2019-03-28 | — | — | US | disclosed |
| US-20190092727-A1 | Piperidine Compounds, Pharmaceutical Composition Comprising The Same And Its Use | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2019-03-28 | — | — | US | disclosed |
| US-10144709-B2 | Piperidine compounds, pharmaceutical composition comprising the same and its use | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2018-12-04 | — | — | US | disclosed |
| US-20170275250-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | SK BIOPHARMACEUTICALS CO LTD (KR) | 2017-09-28 | — | — | US | disclosed |
| US-20170275250-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | SK BIOPHARMACEUTICALS CO LTD (KR) | 2017-09-28 | — | — | US | disclosed |
| US-20170275250-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | SK BIOPHARMACEUTICALS CO LTD (KR) | 2017-09-28 | — | — | US | disclosed |
| US-9676718-B2 | Piperidine compounds, pharmaceutical composition comprising the same and its use | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2017-06-13 | — | — | US | disclosed |
| US-9676718-B2 | Piperidine compounds, pharmaceutical composition comprising the same and its use | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2017-06-13 | — | — | US | disclosed |
| US-9676718-B2 | Piperidine compounds, pharmaceutical composition comprising the same and its use | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2017-06-13 | — | — | US | disclosed |
| US-9593102-B2 | Piperidine compounds, pharmaceutical composition comprising the same and its use | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2017-03-14 | — | — | US | disclosed |
| EP-0903349-B1 | CCR-3 receptor antagonists | HOFFMANN LA ROCHE (CH) | 2006-01-04 | — | — | EP | disclosed |
| WO-2005004865-A1 | USE OF 5-HT4(A)-SEROTONIN RECEPTOR AGONISTS | GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN (DE) | 2005-01-20 | — | — | WO | disclosed |
| US-20040266782-A1 | Cyclic amine derivatives-CCR-3 receptor antagonists | GONG LEYI (US) | 2004-12-30 | — | — | US | disclosed |
| US-6770650-B2 | CHEMOKINE RECEPTOR (CCR) ANTAGONISTS SUCH AS N-(1(S)-(4-(3,4-DICHLOROBENZYL)PIPERAZIN-1-YLMETHYL)-2-METHYLPROPYL)-4 -METHYLBENZAMIDE DIHYDROCHLORIDE SALT FOR TREATMENT OF ASTHMA | SYNTEX (U.S.A.) LLC | 2004-08-03 | — | — | US | disclosed |
| US-6683074-B1 | PYRROLIDINYL, PIPERAZINYL AND AZEPINYL DERIVATIVES; INFLAMMATORY OR ALLERGIC DISEASES | SYNTEX (U.S.A.) LLC | 2004-01-27 | — | — | US | disclosed |
| US-20030153577-A1 | Cyclic amine derivatives-CCR-3 receptor antagonists | ROCHE BIOSCIENCE | 2003-08-14 | — | — | US | disclosed |
| US-6339087-B1 | FOR THERAPY OF INFLAMMATORY OR ALLERGIC DISEASES ARE SELECTED FROM ASTHMA, ALLERGIC RHINITIS, HYPERSENSITIVITY LUNG DISEASES, HYPERSENSITIVITY PNEUMONITIS, EOSINOPHILIC PNEUMONIAS, INFLAMMATORY BOWEL DISEASES, PSORIASIS, DERMATITIS | SYNTEX (U.S.A.) LLC | 2002-01-15 | — | — | US | disclosed |
| US-6323223-B1 | CCR-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, METHODS FOR THEIR USE AND METHODS FOR PREPARING THESE COMPOUNDS. | SYNTEX (U.S.A.) LLC | 2001-11-27 | — | — | US | disclosed |
| EP-0903349-A2 | CCR-3 receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 1999-03-24 | — | — | EP | disclosed |
| EP-0774460-A1 | BENZOIC ACID COMPOUND AND USE THEREOF AS MEDICINE | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266782-A1 | Cyclic amine derivatives-CCR-3 receptor antagonists | CCR3, CCR1, CCRL2 | HTR4 505/4885DRD2 768/4885DRD4 1752/4885 |
| US-20170275250-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | PGC, VIP, PIGO | HTR4 308/4885DRD2 126/4885DRD4 317/4885 |
| US-10144709-B2 | Piperidine compounds, pharmaceutical composition comprising the same and its use | PGC, VIP, PIGO | HTR4 308/4885DRD2 126/4885DRD4 317/4885 |
| US-20190092727-A1 | Piperidine Compounds, Pharmaceutical Composition Comprising The Same And Its Use | PGC, VIP, PIGO | HTR4 308/4885DRD2 126/4885DRD4 317/4885 |
| US-20030153577-A1 | Cyclic amine derivatives-CCR-3 receptor antagonists | CCR3, CCR1, CCRL2 | HTR4 505/4885DRD2 768/4885DRD4 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.